Purpose of the study. A comparative analysis of the intensity of lipid peroxidation and the functioning of various units of the antioxidant system in the blood of patients with malignant pancreatic lesions and with chronic pancreatitis.Patients and Methods. The content of malondialdehyde (MDA) and diene conjugates, the activity and content of antioxidant enzymes (superoxide dismutase, catalase, glutathione reductase, glutathione peroxidase), the content of reduced glutathione and blood thiol status, as well as the content of vitamins E and A (as indicators of the non-enzymatic link of the antioxidant system), were studied in the blood of 51 patients before treatment and 22 donors. Based on a histological study of tumors, patients were divided into groups: neuroendocrine pancreatic cancer, pancreatic adenocarcinoma, pancreatic adenocarcinoma with a neuroendocrine component; a group of patients with chronic pancreatitis was also identified.Results. According to most of the studied parameters, neuroendocrine cancer differs from pancreatic adenocarcinoma in a more pronounced imbalance in the functioning of all units of the antioxidant system, which contributes to a greater intensification of free radical processes. Chronic pancreatitis was characterized by a lower content of all the studied antioxidant enzymes, as well as a decrease in the thiol status of the blood as compared with a malignant pancreatic lesion, which was possibly associated with the highest MDA level in the plasma of patients with chronic pancreatitis. At the same time, the content of vitamin E in chronic pancreatitis was significantly higher than for adenocarcinoma and adenocarcinoma with a neuroendocrine component.Conclusions. The most pronounced violation of oxidative status is one of the metabolic features of neuroendocrine cancer. Differences revealed in patients with neuroendocrine cancer, adenocarcinoma and pancreatitis can be useful both in the diagnosis of different types of pancreatic lesions and for assessing the state of patients during treatment.
Purpose of the study. Determine the frequency of MiNeN among pancreatic carcinomas and analyze the survival rate of patients depending on the percentage of cells with neuroendocrine differentiation in the tumor.Materials and methods. The current study included 31 patients with a pancreatic tumor who received surgical treatment at the Rostov Cancer Research Institute. An immunohistochemical study was conducted on biomarkers of chromogranin A, synaptophysin, and ki-67 for these patients. Based on the data obtained, 4 groups for neuroendocrine differentiation were identified.Results. The direct effect of neuroendocrine differentiation on the survival of patients with histologically confirmed pancreatic ductal adenocarcinoma has been proven. Among the sample of 31 patients, neuroendocrine differentiation was revealed in 24 cases (77%), of which 3 cases of MiNeN (10.3%) were detected. It is also proven relationship between neuroendocrine and patient survival, where an increase percent of positive cells in tumors (chromogranin A or synaptophysin) means a better prognosis. Chromogranin A is a more significant predictor of survival compared to synaptophysin. The largest difference in survival was between negative expression of chromogranin A and the presence of more than 1% positive cells in the tumor.Conclusion. We supposed that it is necessary to use neuroendocrine markers (chromogranin A and synaptophysin) in the diagnosis of ductal adenocarcinomas, even without histological signs of neuroendocrine differentiation. This will allow for a larger amount of data to determine their significance as prognostic markers.
Pancreatic cancer (PC) is a lethal malignant tumor characterized by a rapid progression, invasiveness and resistance to radiochemotherapy. The development of biomarkers for the early diagnosis of the disease is relevant. Angiogenesis has been identified as a key factor in a number of pathological conditions, including cancer. The proangiogenic signaling molecule – vascular endothelial growth factor (VEGF) and its receptors play a central role in tumor angiogenesis. In this review, we also highlight the dual role of growth factor-β (TGF-β) and touch upon the prospects for therapeutic effects on targets associated with TGF-β signaling in pancreatic cancer. A growing interest is attracted to the role of insulin-like growth factors IGF-I and IGF-II in cancer diseases. IGF-I and its receptor are highly expressed on the surface of pancreatic cancer cell lines that initiate the transduction of intracellular signals associated with the proliferation, invasion and expression of angiogenesis mediators. And so, the study of markers and growth factors may be a new, viable option for the diagnosis and treatment of pancreatic cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.